Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 1

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 1
---
 current product candidates and future therapeutic candidates contain psychedelic substances, and may be subject to controlled substance laws and regulations.                                     
  Our product candidates contain potentially controlled substances, the use of which may generate public controversy.                                                                                   
  Any clinical trials that we may conduct in the future to demonstrate substantial evidence of the safety and effectiveness of product candidates that we may identify and pursue for their intende...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time consuming and uncertain.                                                 
  The results of early-stage clinical trials and preclinical studies may not be predictive of future results.                                                                                           
  Research and development of drugs targeting the Central Nervous System is particularly difficult.                                                                                                     
  If we encounter difficulties enrolling patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.                                             
  Use of our product candidates could be associated with side effects, adverse events or safety risks.                                                                                                  
  Even if any of our current or future product candidates receives regulatory approval, it may fail to achieve market acceptance necessary for commercial success.                                      
  If we are unable to obtain regulatory approval in one or more jurisdictions for any product candidates that we may identify and develop, our business will be substantially harmed.                   
  Interim, “top-line,” and preliminary data from our clinical trials that we announce or publish from time to time may change, which could result in material changes in the final data.                
  Certain of the product candidates we are developing are complex and difficult to manufacture. We could experience manufacturing problems that result in delays or otherwise harm our business.        
  We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to drug product candidates.                                          
  For any approved product, we will be subject to ongoing regulatory obligations and continued regulatory review and we may be subject to penalties if we fail to comply.                               

Risks Related to Commercialization

  If we are unable to establish sales and marketing capabilities or enter into agreements to sell and market any product candidates, we may not be successful in commercializing those product cand...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  The third-party payor coverage and reimbursement status of newly approved products is uncertain